Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2Multiple Myeloma 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Lymphoma 1Lipodystrophy, Congenital Generalized 1Leukemia 1Glioblastoma 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Tetanus Toxoid × Clear all
NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
80 enrolled 33 charts
Tumor-Agnostic

Neoplasms

NCT00000105 2017-11-29

Vaccination With Tetanus and KLH to Assess Immune Responses.

Masonic Cancer Center, University of Minnesota

Terminated
112 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡